Difference between revisions of "Arsenic trioxide (Trisenox)"
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Acute | + | *[[Acute promyelocytic leukemia]] |
==Patient drug information== | ==Patient drug information== | ||
Revision as of 14:15, 19 June 2013
General information
Class/mechanism: Causes damage or degradation of PML-RAR alpha fusion protein, causes apoptosis-type changes in NB4 human promyelocytic leukemia cells in vitro.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Arsenic trioxide (Trisenox) patient drug information (Chemocare)[3]
- Arsenic trioxide (Trisenox) patient drug information (UpToDate)[4]